New CHO Cell Culture Media Platform for Optimized Cell Growth
Merck Millipore has launched its Cellvento CHO platform of cell culture media and companion feed formulations for batch, fed-batch and perfusion applications. Available in liquid and powder form, the chemically defined, non-animal-origin media deliver superior cell growth and productivity for various CHO cell types used in biopharmaceutical development and manufacturing.
The Cellvento CHO platform includes cell line and process-specific media and feed compositions, allowing selection of the optimal media formulation for a given application. The range of products also offers customers the flexibility to choose the most suitable product to achieve the best possible performance results for their specific cell line.
The platform provides a variety of formulations designed to meet the needs of CHO-S, CHO-DHFR negative and CHO-K1 suspension cell types. All formulations offer excellent powder homogeneity and consistency, resulting in strong lot-to-lot reproducibility. The media are supported by comprehensive regulatory information on their manufacture, characterization and control.
"Biopharmaceutical manufacturers require cell culture media that will deliver the most robust product yield, quality and consistency," said Andrew Bulpin, executive vice president of Merck Millipore, Process Solutions Business Area. "The Cellvento CHO platform offers a variety of formulations, all backed by Merck Millipore's strong chemical, raw material and regulatory expertise. This range of options ensures customers have the flexibility to select the best media for their specific process, optimizing their production and ultimately accelerating time to market."
The production media all have companion feed formulations to extend the cell production phase and maximize yields.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...